Thiazole and thiazolidene derivatives of p-hydroxybenzohydrazide were found having anti cancer activity. These compounds were showed the inhibitory effect against various cancerous cell lines. An attempt was made to find the correlation in these anticancer agents as epidermal growth factor receptor (EGFR): tyrosine kinases inhibitors. N'- [4-(4-substituted-phenyl)-3-(substituted-phenyl)-1,3-thiazol-2(3H)-ylidene]-4-hydroxybenzohydrazide compounds (I-IV) and N'-[3-(substituted-phenyl)-4-oxo-1,3-thiazolidin-2-ylidene]-4-hydroxybenzohydrazide compounds (VVIII) were used in the docking study. Compounds were evaluated in terms of GScore, Dockscore, H-bonding interactions, electrostatic interactions. In the docking study with receptor 1M17, the numbers of H-bond interactions showed crucial role in relation with activity. As standard drug was compared with the compounds (IV-VII); this showed good H-bond interactions and correlated with their anticancer activity.
